Auspex Pharmaceuticals hopes to have an auspicious effect on orphan diseases. The company's pipeline includes candidates to treat hyperkinetic movement disorders associated with Huntington's disease, tardive dyskinesia, and Tourette syndrome, which are considered orphan diseases because they affect fewer than 200,000 people in the US. Auspex has taken the only approved treatment for Huntington's-associated movements and altered it chemically to produce a treatment with fewer side effects that doesn't need to be taken as often. The firm's pipeline contains treatments for a handful of other diseases. Auspex raised $84 million in an IPO in early 2014, but Teva  bought the company in 2015 for $3.2 billion.